{"product_id":"ocs-ansoff-analysis","title":"(OCS) Oculis Holding AG ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Oculis Holding AG Ansoff Matrix Analysis shows how the company can grow via market penetration, market development, product development, and diversification; it’s designed for strategy, investment, or research use and presents findings in a ready-to-apply format. This page contains a real preview\/sample of the analysis so you can judge style and substance before buying—purchase the full version to get the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOCS-01 Phase 3 DME\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-01 is Oculis Holding AG’s lead Phase 3 topical dexamethasone program for diabetic macular edema, a market where anti-VEGF injections already dominate care. The global DME treatment market is estimated in the billions, and in the U.S. about 750,000 people have DME, so a non-invasive eye-drop format can win share by reducing injection burden. That makes this a clear market penetration play in an established retina segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTopical dexamethasone eye-drop\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTopical dexamethasone eye-drop is a direct share-grab in diabetic macular edema, targeting a market where intravitreal anti-VEGF therapy still dominates care. Its topical route could lower the treatment burden tied to repeated injections and fit a familiar ophthalmic channel. With global diabetes at 537 million adults in 2026, the addressable DME pool stays large and clinically active.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOCS-02 Phase 2b dry eye disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-02 is in Phase 2b for keratoconjunctivitis sicca, a dry eye market that already affects about 16 million diagnosed patients in the U.S. and over 300 million people worldwide. The market-penetration play is clear: win share inside an existing, high-volume ophthalmology segment with a novel biologic eye drop. If approved, Oculis Holding AG could compete in a market that generated about USD 4.2 billion in global dry-eye drug sales in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAnterior and posterior segment eye drops\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOculis Holding AG uses eye drops in both anterior and posterior segment disease, so it can win share in 2 existing ophthalmic treatment areas instead of chasing a single niche. Its lead programs span retinal and inflammatory eye care, including OCS-01 and OCS-02, which supports broader specialist adoption. That matters because ophthalmology is a high-volume market: diabetes affects 537 million adults worldwide, feeding demand for retinal care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 treatment areas\u003c\/li\u003e\n\u003cli\u003eBroader specialist reach\u003c\/li\u003e\n\u003cli\u003eRetinal care demand is large\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDME and dry eye specialist focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOculis Holding AG’s pipeline stays focused on DME and dry eye disease, two large, familiar ophthalmic markets. This narrow scope can speed specialist awareness with retina and ocular-surface doctors and keeps sales, trials, and medical education tightly aimed at proven need areas. In 2025, dry eye affects millions of patients and DME remains a leading cause of vision loss in diabetes, supporting clear demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus improves specialist recall.\u003c\/li\u003e\n\u003cli\u003eLower launch complexity than broad expansion.\u003c\/li\u003e\n\u003cli\u003eTargets high-volume eye-care channels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOculis Targets Big Ophthalmology Markets with Eye-Drop Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOculis Holding AG’s market penetration play is to win share in existing ophthalmology markets with OCS-01 for diabetic macular edema and OCS-02 for dry eye disease. In 2026, diabetes affects 537 million adults worldwide, and dry eye drug sales reached about USD 4.2 billion in 2025, so both targets are large and proven. The eye-drop format lowers injection burden and fits current specialist channels.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCS-01\u003c\/td\u003e\n\u003ctd\u003eDME\u003c\/td\u003e\n\u003ctd\u003e537 million adults with diabetes in 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCS-02\u003c\/td\u003e\n\u003ctd\u003eDry eye\u003c\/td\u003e\n\u003ctd\u003eUSD 4.2 billion sales in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOutlines Oculis Holding AG’s growth strategy across market penetration, market development, product development, and diversification\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Oculis Holding AG Ansoff Matrix to quickly identify and reduce growth strategy uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise list of primary sources validating Oculis Holding AG growth assumptions to quickly support Ansoff Matrix decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOCS-01 beyond one retina setting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-01 for diabetic macular edema sits in a large diabetic eye-care pool: the IDF estimated 589 million adults with diabetes in 2024, and about 1 in 3 can develop diabetic retinopathy. If Oculis Holding AG shows durable vision gains, the same asset could move from a narrow retina use to broader specialist adoption. That is classic market development: one candidate, wider prescriber reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOCS-02 broader dry-eye populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-02 targets keratoconjunctivitis sicca, the core dry-eye market, so success could move Oculis Holding AG into a much larger pool than the roughly 344 million people living with dry eye globally. As a biologic eye drop, it can be used across more care settings, from specialist clinics to routine ophthalmology, if development holds up. That matters because moderate-to-severe cases may account for about 20% of patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOCS-05 acute optic neuritis entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-05’s move into acute optic neuritis is a clear market development step: Oculis Holding AG is taking an existing asset into a new neuro-ophthalmology setting while staying inside the eye-disease field. The addressable market is still small but high-value, since acute optic neuritis affects roughly 1 to 5 per 100,000 people a year.\u003c\/p\u003e\n\u003cp\u003eThis entry can expand Oculis Holding AG beyond dry eye and retinal disease, and it supports pipeline breadth without starting from zero. In Ansoff terms, it is new market development with an existing candidate, not a new-product launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOCS-05 glaucoma and diabetic retinopathy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOCS-05 extends Oculis Holding AG beyond optic neuritis into glaucoma and diabetic retinopathy, two large specialist eye-care markets. Glaucoma affects about 80 million people worldwide and diabetic retinopathy about 103 million, so one asset can open two adjacent revenue pools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eSame molecule, multiple retinal\/optic uses\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAdjacencies reduce R\u0026amp;D rework\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLarge addressable patient base\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOCS-05 geographic atrophy and neurotrophic keratitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOCS-05’s links to geographic atrophy and neurotrophic keratitis extend Oculis Holding AG beyond diabetic eye disease into larger retinal and corneal pools. Geographic atrophy affects about 5 million people worldwide, and neurotrophic keratitis is rare but sight-threatening, with U.S. prevalence estimates near 5 per 10,000. That is indication-led market development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands from retina to cornea\u003c\/li\u003e\n\u003cli\u003eTaps larger unmet-need pools\u003c\/li\u003e\n\u003cli\u003eSupports broader partner value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOculis Expands Eye Assets Into Massive New Patient Pools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOculis Holding AG’s market development is about taking the same eye assets into bigger adjacent patient pools. OCS-01 could reach part of the 589 million adults with diabetes, while OCS-02 fits the 344 million global dry-eye pool. OCS-05 also opens new specialist uses in optic neuritis, glaucoma, and diabetic retinopathy.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eKey size\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCS-01\u003c\/td\u003e\n\u003ctd\u003eDME\u003c\/td\u003e\n\u003ctd\u003e589m diabetes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCS-02\u003c\/td\u003e\n\u003ctd\u003eDry eye\u003c\/td\u003e\n\u003ctd\u003e344m cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eOculis Holding AG Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOCS-01 Phase 3 advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-01 is Oculis Holding AG’s most advanced candidate, and its Phase 3 move is core product development in the Ansoff Matrix. In DME, a late-stage asset can matter because diabetes affects 537 million adults globally, with macular edema a major vision-risk driver. Advancing OCS-01 also shifts Oculis closer to a first-in-class, non-invasive treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOCS-02 Phase 2b biologic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-02 is Oculis Holding AG’s topically administered biologic in Phase 2b, so it is a clear new-product move in the dry eye disease market. A biologic eye drop is a differentiated bet because it aims to add a distinct mechanism of action versus standard lubricants and anti-inflammatories. In a large market where dry eye affects tens of millions of patients in the U.S. alone, even modest share gains can drive meaningful upside if Phase 2b data support the 2026 development path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOCS-05 neuroprotective agent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-05 is Oculis Holding AG’s new neuroprotective agent and a clear product-development move in the Ansoff Matrix. It uses a distinct mechanism of action versus the Company’s topical steroid and biologic programs, so it expands the pipeline beyond existing eye-disease treatments. With a Phase 2-stage approach, it adds a separate clinical path and higher-value innovation potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTopical formulation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOculis Holding AG’s topical formulation platform is a core product-development engine: it turns eye science into drop-based candidates for both anterior and posterior diseases, reducing reliance on injections. The platform underpins OCS-01, a Phase 3 candidate for diabetic macular edema and non-infectious uveitis, helping Oculis build a broader pipeline from one delivery method.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrop-based delivery, not injectables\u003c\/li\u003e\n\u003cli\u003eSupports anterior and posterior eye disease\u003c\/li\u003e\n\u003cli\u003eDrives pipeline expansion from science\u003c\/li\u003e\n\u003cli\u003eOCS-01 is the lead clinical example\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eThree-candidate pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOculis Holding AG’s three-candidate pipeline: OCS-01, OCS-02, and OCS-05. Three assets spread risk and give the Company multiple shots at new product creation, while each program targets a distinct ophthalmology or neuro-ophthalmology need. That broadens the addressable market and can lift pipeline value if even one asset reaches late-stage success.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOCS-01: eye disease focus\u003c\/li\u003e\n\u003cli\u003eOCS-02: ophthalmic inflammation\u003c\/li\u003e\n\u003cli\u003eOCS-05: neuro-ophthalmology need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOculis’ Three-Asset Pipeline Fuels Growth Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduct development is Oculis Holding AG’s main growth lever, led by OCS-01, OCS-02, and OCS-05. OCS-01 is in Phase 3 for diabetic macular edema, OCS-02 is in Phase 2b for dry eye disease, and OCS-05 is in Phase 2 for neuroprotection. The mix gives Oculis Holding AG three shots at new products from one topical platform.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCS-01\u003c\/td\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003eNew ophthalmic therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCS-02\u003c\/td\u003e\n\u003ctd\u003ePhase 2b\u003c\/td\u003e\n\u003ctd\u003eNew biologic eye drop\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCS-05\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003ctd\u003eNew neuroprotective agent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOCS-05 neuro-ophthalmology expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-05 pushes Oculis Holding AG beyond retina and dry-eye care into neuro-ophthalmology, so it is a clear diversification move in Ansoff terms: new product, new market. Acute optic neuritis is uncommon, with a yearly incidence of about 1 to 5 cases per 100,000 people, and it is a distinct disease class from the company’s core eye programs. That shift can widen Oculis Holding AG’s addressable market, but it also adds higher clinical and commercial risk because neurology and ophthalmology adoption paths are different.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlaucoma diabetic retinopathy geographic atrophy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOCS-05’s reach into glaucoma, diabetic retinopathy, and geographic atrophy spreads Oculis Holding AG across three separate high-need eye markets. Glaucoma affects about 80 million people worldwide, diabetic retinopathy about 103 million, and geographic atrophy about 5 million, so one program can tap multiple large pools. That mix helps reduce single-indication risk and broadens the upside in Oculis Holding AG’s pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurotrophic keratitis entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurotrophic keratitis gives OCS-05 a third disease angle, adding corneal disease to Oculis Holding AG’s mix beyond diabetic macular edema and dry eye. Neurotrophic keratitis is rare, with U.S. prevalence estimates around 5 per 10,000 people, so it can support a niche but high-value entry. That diversification can spread clinical risk and widen the addressable market if OCS-05 translates well across retinal and corneal indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRetina cornea optic nerve mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOculis Holding AG’s pipeline spans 3 distinct eye-disease areas—retina, cornea, and optic nerve—so the company is not tied to one ocular segment. That spread lowers concentration risk and fits a classic diversification move in the Ansoff Matrix across multiple eye-disease markets. The broader mix also gives Oculis more shots at value creation than a single-target pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 ocular segments: retina, cornea, optic nerve\u003c\/li\u003e\n\u003cli\u003eReduces single-market dependence\u003c\/li\u003e\n\u003cli\u003eExpands clinical and commercial optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSteroid biologic neuroprotective portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOculis has three clinical programs spanning steroid, biologic, and neuroprotective science, so it is diversifying by both mechanism and disease area. That mix reduces dependence on one asset class and supports a broader ophthalmology pipeline, with OCS-01, OCS-02, and OCS-05 each aimed at distinct unmet needs in eye disease.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThree platforms, not one\u003c\/li\u003e\n\u003cli\u003eDiversifies mechanism risk\u003c\/li\u003e\n\u003cli\u003eSpreads across eye diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOculis Expands Beyond Eye Care, Trading Lower Risk for Bigger Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOculis Holding AG’s diversification centers on OCS-05 moving from core eye care into optic nerve, cornea, and retina uses, which lowers single-indication risk and broadens its market reach. The key trade-off is higher clinical and commercial risk because neuro-ophthalmology is a different selling path than ophthalmology.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegments\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOptic neuritis incidence\u003c\/td\u003e\n\u003ctd\u003e1–5\/100,000\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaucoma patients\u003c\/td\u003e\n\u003ctd\u003e80M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetic retinopathy\u003c\/td\u003e\n\u003ctd\u003e103M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234739069193,"sku":"ocs-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ocs-ansoff-matrix.webp?v=1785727228","url":"https:\/\/dcfanalyst.com\/products\/ocs-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}